While the roster of 48 drugs the FDA approved in 2019 didn’t break any records with the sheer number, it was remarkable in one aspect: The agency reached deep into a group of therapies they didn’t need to make a decision on until later this year, in some cases speeding drugs up by months ahead of even priority review deadlines.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,